Bharat Biotech submits intranasal vaccine data to drug regulator

Bharat Biotech International Limited (BBIL) on Monday said its intranasal Covid-19 vaccine BBV154 has proved to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials for the vaccine as a primary and as a heterologous booster and it has submitted the data from both the Phase III trials for approval to India’s regulatory authorities.